Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06879041 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 1 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 95
- Enrollment target
- 15
- Study locations
NCT06879041 is a Phase 1 study of Metastatic Castration-Resistant Prostate Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 95 participants, below the 197-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (52% lower). The trial reports 15 study locations across 11 states.
The verdict
NCT06879041, a Phase 1 study of Metastatic Castration-Resistant Prostate Cancer, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 95 participants
- Enrollment target
- 15
- Study locations
Study Summary
The main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275.
Conditions Studied
Interventions
- DRUG AZD2287
- DRUG AZD2275
- DRUG AZD2284
Study Locations (15)
Other
- Research Site - East Melbourne
- Research Site - CapeTown
- Research Site - Durban
- Research Site - Pretoria
Florida
- Research Site - Miami
- Research Site - Tampa
California
- Research Site - Palo Alto
Illinois
- Research Site - Chicago
Louisiana
- Research Site - Metairie
Massachusetts
- Research Site - Boston
Minnesota
- Research Site - Rochester
Nebraska
- Research Site - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2025-03-10 |
| Est. Completion | 2029-04-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06879041
The ClinicalTrials.gov registry entry for NCT06879041 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 197-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (52% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which AZD2287 is the first listed.
NCT06879041 reports 15 study locations spanning 11 distinct geographic areas - top geographies include Other, Florida, California.
Frequently Asked Questions
What is clinical trial NCT06879041 about?
NCT06879041 is a clinical study titled "A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer". The main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275.
What is the current status of trial NCT06879041?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 95 participants. The study started on 2025-03-10. Estimated completion is 2029-04-16.
What conditions does trial NCT06879041 study?
This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer.
What interventions are being tested in trial NCT06879041?
The interventions under investigation include: AZD2287 (DRUG), AZD2275 (DRUG), AZD2284 (DRUG).
Who is sponsoring clinical trial NCT06879041?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06879041 being conducted?
This trial has 15 study locations across California, Florida, Illinois, Louisiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Castration-Resistant Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer
RECRUITING · Phase 1
-
A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study
RECRUITING · Phase 1
-
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
RECRUITING · Phase 1
-
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RECRUITING · Phase 1
-
A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer
RECRUITING · Phase 1
-
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.